Wave life sciences announces initiation of phase 1 inlight clinical trial of wve-007 in obesity

Wve-007 is a novel, long-acting galnac-sirna targeting inhbe mrna – a genetically validated target that provides a new approach for healthy, sustainable weight loss (fat loss with muscle preservation)

WVE Ratings Summary

WVE Quant Ranking